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Praziquantel, a broad spectrum anthelmintic drug, cannot be found in acceptable dosage forms 
for elderly patients, paediatric patients, and for veterinary use. In fact, very little has been done up 
to now in the formulation of liquid dosage forms, being they always formulated for parenteral 
administration. To beat this important challenge, it was accomplished a comprehensive analysis of 
the influence of two elementary physicochemical aspects, i.e. surface thermodynamic and 
electrokinetic properties, on the colloidal stability of praziquantel nanosuspensions. The 
hydrophobic character of the drug, intensely determining the flocculation curves, was confirmed by 
the thermodynamic characterization. The electrophoretic characterization, in combination with the 
sedimentation and relative absorbance versus time curves, highlighted that the electrical double 
layer thickness and the surface charge can play an essential role in the stability of the 
pharmaceutical colloid. Finally, it was demonstrated that controlling the pH values and the 
incorporation of electrolytes can help in formulating praziquantel aqueous nanosuspensions with 
appropriate stability and redispersibility behaviours for pharmaceutical use. 
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Helminths are parasitic worms characterized by a bilateral symmetry and by an elongated, flat, 
or round morphology. Depending on the specie, the size of these invertebrates varies from 
millimeters to meters. In the group, nematodes include soil-transmitted helminthes or the so-called 
intestinal worms commonly responsible for helminthiasis, and filarial worms that are described to 
cause lymphatic filariasis and onchocerciasis. With respect to platyhelminths, trematodes or flukes 
(i.e. schistosomes) and cestodes or tapeworms are frequently defined to be responsible for parasitic 
infections in humans and animals (Hotez et al., 2008; Hotez and Aksoy, 2017). Helminth infestation 
causes morbidity and mortality, affecting cognitive processes, compromising the nutritional status, 
inducing tissue reactions and causing intestinal obstruction or rectal prolapse. Preschool children 
and school-aged children, including adolescents, are commonly infected by intestinal worms and 
schistosomes, experiencing stunted growth and cognitive and memory impairments (resulting in 
cognitive and educational deficits) (Crompton and Nesheim, 2002; Hotez and Aksoy, 2017). 
The neglected tropical disease Bilharzia, or schistosomiasis, is an acute and chronic parasitic 
infection that can result in serious damage to internal organs. It is caused by trematodes belonging 
to the genus Schistosoma, principally by Schistosoma mansoni, S. japonicum, and S. haematobium 
(Lustigman et al., 2012; Raso et al., 2007). The disease is a significant public health issue with 
severe socio-economic impacts in developing countries (King et al., 2005; Steinmann et al., 2006). 
The acute phase of the disease is generally asymptomatic, but fever, cough, diarrhoea, a red and 
itchy rash, and joint and abdominal pains are usually described (Olveda et al., 2013; Ross et al., 
2013). On the opposite, acute local inflammatory lesions are reported in chronic schistosomiasis to 
be produced by the remaining trematode eggs trapped in tissues, while massive infestations are 
characterized by pseudopolyps in bladder and intestinal light (Colley et al., 2014). 
Praziquantel (PZQ) is a broad spectrum and very effective anthelmintic drug being not only 
used in the treatment of schistosomiasis, but also in the prevention and early treatment of 











in all species of Schistosoma (Caffrey, 2007), and it is included in the World Health Organization 
(WHO) Model List of Essential Medicines for Children (Hoppu and Sri Ranganathan, 2015). 
Additionally, PZQ is a highly lipophilic agent characterized by a low aqueous solubility and a high 
permeability, which is thus classified as a Class II drug according to the Biopharmaceutics 
Classification System (BCS) (Linderberg et al., 2004). The hydrophobic character of the compound 
has limited the development of acceptable (i.e. liquid) dosage forms for elderly patients, paediatric 
patients, and for veterinary use. Indeed, the common marketed formulations of PZQ are oral solid 
dosage forms (e.g. tablets) that frequently are improper to those groups of patients and for a flexible 
drug dosing (Conway et al., 2013). Regarding the formulation of liquid PZQ dosage forms, little has 
been performed heretofore: the active agent is only described in oily suspensions (Qian et al., 2017; 
Tang et al., 2016), or loaded to liposomes (Mourão et al., 2005) and nanoparticulate systems, e.g. 
solid lipid nanoparticles (Xie et al., 2011), poly(methyl methacrylate) nanoparticles (Malhado et al., 
2016), and chitosan nanoparticles (Torabi et al., 2018), being they always formulated for parenteral 
administration. 
The present contribution has been devoted to the definition of a basic aspect in the formulation 
of PZQ nanosuspensions as oral liquid dosage forms for human and veterinary use, i.e. the control 
and prediction of the stability and redispersibility properties of the colloid. Given their relevance to 
these characteristics (Arias et al., 2009; Gallardo et al., 2000, 2003), the surface thermodynamics 
(hydrophilic/hydrophobic nature) and the electrical properties of the drug/liquid interface were 












2. Materials and methods 
2.1. Materials 
Chemicals were of analytical quality from Panreac Química S.A.U. (Spain), except for PZQ 
(Guinama S.L.U., Spain; complying the European Pharmacopoeia requirements), formamide 
(Carlo Erba, Italy) and diiodomethane (Merck KGaA, Germany). Water used was previously 
deionized and filtered (Milli-Q Academic System, Millipore, Spain). 
 
2.2 Methods 
2.2.1. Preparation of the PZQ aqueous nanosuspensions 
Aqueous nanodispersions of the anthelmintic drug (0.5%, w/v) were obtained by progressive 
incorporation of the solid to water under sonication. Prior to the addition of PZQ, the microtip 
of the sonicator was immersed in the aqueous phase, leaving one cm distance from the bottom of 
the flask without touching its walls. Pulsed mode, with a cycle of 50%, was used because it 
facilitated a better temperature control than continuous mode operation, and avoided a temperature 
increase in the dispersion. For further temperature control, flasks were surrounded with ice during 
the process. 
An alternative procedure, that could be easily scalable at the industrial scale, consisted in the 
dropwise addition of the drug particles, under mechanical stirring (3,000 rpm) to the aqueous 
dispersion medium. In accordance to the sonication method, it also assured the generation of 
homogeneous PZQ nanosuspensions. 
 
2.2.2. Size of the PZQ particles 
Mean hydrodynamic diameters (and polydispersity index, PdI) of the anthelmintic particles 
were determined by dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments Ltd., UK) (n 
= 12). The scattering angle was set at 90º, and the measurements of the aqueous dispersions (≈ 











The technique was further used to evaluate the evolution with time (up to six months) of the 
particle size in nanosuspensions stored under standard conditions (4.0 ± 0.5 ºC). 
 
2.2.3. Hydrophobic/hydrophilic character 
To define the wettability (hydrophobic / hydrophilic character) of PZQ particles, it was used a 
surface thermodynamic model capable of evaluating the surface-free energy components of the 
solid, 
S
  (Adamson and Gast, 1997; van Oss, 2006). This is a well-known model that has clearly 
demonstrated its suitability in colloids and suspensions formulated for pharmaceutical applications 
(Arias et al. 2008, 2009; Cózar-Bernal et al., 2010; Viota et al., 2010). Measurements of the contact 
angle (θ) of three liquids (water, formamide, and diiodomethane) on pellets of powdered PZQ solids 
(diameter ≈ 1 cm) were done at 25.0 ± 0.5 ºC, using a goniometer (model 100/07/00, Ramé-Hart, 
Inc., USA) equipped with a charge-coupled device (CCD) camera and a digital image analysis of 
drop pictures. Pellets were prepared by compressing the dry powder in a hydraulic press (Specac™, 
UK) set to 2 Ton during 5 min. 
 
2.2.4. Stability of the aqueous nanosuspensions 
Complementarily to the electrophoretic study (see Section 2.2.5.), two methods were used to 
characterize the stability of PZQ nanosuspensions (0.5%, w/v). The first one consisted in the 
measurement of the sediment volume, Vs, after keeping these dispersions in 0.1 L cylinders (inner 
radius ≈ 1.2 cm) at 25.0 ± 0.5 ºC. The flocculation ratio (F%) was then calculated as Vs/V0 (%), 
where V0 is the initial volume of the suspension (Matthews and Rhodes, 1970).  
The second method, suitable for dilute pharmaceutical dispersions (Arias et al. 2009; Cózar-
Bernal et al., 2010), was based on the measurement as a function of time of the optical absorbance 
(A) of drug nanosuspensions (λ = 500 nm; PerkinElmer UV/Vis Lambda 25 spectrophotometer, 











Finally, redispersibility of the PZQ sediments was evaluated by visual inspection of the 
nanosuspensions after placing them in an ultrasonic bath (model Branson 5200E4, Branson, USA; 
set at 40 kHz, with a sonic power of 100W) (Arias et al. 2009; Cózar-Bernal et al., 2010). Results 
were found to be equal to moderate hand shaking of the suspensions (≈ 3 min). 
 
2.2.5. Surface electrical properties of PZQ particles 
The electrophoretic properties of the FBZ colloids (≈ 0.05%, w/v) were analysed (Zetasizer 
Nano ZS device) as a function of both electrolyte concentration (ionic strength), i.e. NaCl, 
CaCl2·4H2O, or AlCl3·6H2O (concentrations from 0.01 mM to 0.1 M), and pH (adjusted with either 
NaOH or HCl). These well-known electrolytes (NaCl, CaCl2, and AlCl3) are classically used to 
stabilize aqueous pharmaceutical suspensions (Abrahamsson and Odman, 2008; Arias et al., 2008, 
2009; Cózar-Bernal et al., 2010; Gallardo et al., 2003). NaCl and CaCl2 were approved by the Food 
and Drug Administration (F.D.A.) and, despite AlCl3 has not been yet approved by this 
Administration, it was included in the study to fully analyse the effect of the type of electrolyte and 
its concentration on the stability of PZQ suspensions. Measurements were done after 24 h of contact 
at room temperature under mechanical stirring (100 rpm), and after 2 min equilibration time at 25.0 
± 0.5 ºC. The experimental uncertainty of the measurements was < 3%. 
 
3. Results and discussion 
3.1. Size and surface thermodynamics of PZQ particles 
PZQ particles were found to be of colloidal size and moderately monodisperse. The average 
diameter (± standard deviation) and polydispersity index were 610 ± 70 nm and 0.089, respectively. 
Regarding the wettability of the anthelmintic drug, it is important to define this behaviour in 
aqueous media when preparing a nanosuspension. With that aim, the evaluation of the surface 
thermodynamics of drug particles has demonstrated to be of great help, especially when considering 
the data coming from the non-polar Lifshitz–van der Waals ( 
LW
S
), the electron-donor ( 

S














) components to elucidate the nature of a pharmaceutical solid (Adamson and 
Gast, 1997; Arias et al. 2008; Cózar-Bernal et al., 2010). This study started with the quantification 
of the contact angles (θ) of water, formamide, and diiodomethane on dry PZQ pellets: 83º ± 2º, 53º 
± 1º, and 20º ± 2º, respectively. 
The θ data was used to calculate the γ
S
 components by applying the Young’s equation 
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, components were 47.613 ± 0.542 mJ/m
2
, 2.471 ± 0.754 mJ/m
2
, 
and 0.021 ± 0.008 mJ/m
2
, respectively. Hence, PZQ was found to be a monopolar electron-donor 
solid (van Oss, 2006): this anthelmintic agent can have acid–base interactions with phases of 






 different from zero), even though the acid–base forces do not 
contribute to its cohesion free energy. 
These γ
S
 components further manifest themselves in the hydrophobic/hydrophilic character of 
the drug particles, and they can be used to evaluate the free energy of interaction (ΔGSLS, not 
considering the electrostatic component) between the solid phases immersed in the liquid (van Oss, 
2006). This quantity is written as follows per unit area of interacting particles: 
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(2) 
The negative value of ΔGSLS for the PZQ particles (-78.37 ± 5.48 mJ/m
2
) characterized the 
hydrophobic nature of the drug, this postulating that interfacial interactions will support attraction 
of the nanoparticles to each other in the aqueous media. 
 












Introducing electrolytes in the composition of the dispersion medium has been described to help 
in the control of the electrical surface charge of pharmaceutical formulations based on colloids and 
suspensions (Arias et al. 2008, 2009; Cózar-Bernal et al., 2010; Gallardo et al., 2000, 2003). Thus, 
the significance of characterizing how the stability of the PZQ aqueous nanosuspension depended 
on the electrolyte type and concentration. 
Figs. 1a, 2a, and 3a gather the sedimentation (F%) versus time curves of the PZQ aqueous 
nanosuspensions at their natural pH (pH 5), when NaCl, CaCl2, and AlCl3 were incorporated in 
concentrations up to 10
-1
 M. Independently of the electrolyte type and concentration, the initial 
sediment volume was very low and progressively increased with time to get stable sediments after ≈ 
60 h. Additionally, it was observed a small tendency toward greater flocculation ratios and faster 
settling rates as both the valence of the electrolyte and concentration increased. The hydrophobic 
character of the anthelmintic drug (see Section 3.1.), determining particle aggregation, could be 
behind the absence of more significant differences in the sedimentation profiles even at the very 
low electrolyte concentrations were the drug would tend to settle as individual particles (high zeta 
potential, ζ, see below). 
This behaviour was confirmed by the relative absorbance (optical absorbance A, relative to its 
initial value, A0) versus time curves (Figs. 1b, 2b, and 3b). The ratio A/A0 decreased with time, as 
PZQ particles disappeared out of the light beam during sedimentation. Faster settling rates were 
characteristic of the slightly more voluminous (heavy) sediments probably generated at the greatest 
electrolyte concentrations. 
These stability and redispersibility profiles could be qualitatively explained in the context of the 
DLVO classical theory of the stability of hydrophobic colloids (Hunter, 2001), by considering the 
evolution of the electric double layer properties of the PZQ nanoparticles when varying the 
electrolyte type and concentration (Fig. 4). Regarding the ionic strength, an increase may favour the 
accumulation of counterions closer to the drug surface, and hence a reduction in the electric double 











the PZQ nanoparticles, and accordingly weak electrostatic repulsions between the drug particles 
that determine the fast sedimentation rates and the formation of voluminous sediments (Figs. 1, 2, 
and 3), which complete redispersion was slightly easier. As these repulsions were maximized when 
the electrolyte concentration was reduced, the opposite occurred for the high |ζ| values characteristic 
of the particles, and slow sedimentation of individual particles may be facilitated (Arias et al., 2009; 
Gallardo et al., 2000, 2003). The average particle-particle distance could thus be small, and particles 
will be at the range of van der Waals attractions, packing into compact sediments, difficult to 
redisperse. 
With respect to the valence of the counterion, a similar effect was observed when it was 
increased. The highly charged counterion Al
3+
 was more efficient in reducing the ζ values than the 
divalent Ca
2+
 cation, which in turn was more efficient than Na
+
 (Fig. 4), probably a consequence of 
the Schulze-Hardy rule (briefly described below). In fact, the ζ values were found to be positive 
almost within the range of concentrations investigated for the trivalent cation. As well, the very low 
ζ values generated even at weak ionic strengths for AlCl3 could explain the formation of slightly 
more voluminous aggregates, settling lightly faster (Fig. 3). 
Given the incomplete coverage of the drug surface by counterions at low electrolyte 
concentrations, Cl
–
 ions could reach the solid/liquid interface and an additional increase in the 
negative ζ could take place. This effect was compensated by the double-layer compression coming 
from increasing counterion concentrations. Adsorption of these co-ions may be prevented or 
reduced when the electrolyte concentration (number of cations) was increased. Thanks to the greater 
charge of Al
3+
, this cation was more efficient in this coating effect (strong interaction with the PZQ 
surface), and ζ data moved to positive values (Cózar-Bernal et al., 2010; Ruiz et al., 2004).  
Finally, total redispersion was possible after ≈ 4 and ≈ 1 min of ultrasonic shaking of the 
nanosuspensions with small and high ionic strengths and/or valence of the counterion, respectively. 
In addition, it was observed the maintenance of the original mean particle size (≈ 600 nm) up to five 











of irreversible particle aggregation (generation of macroaggregates) under the standard storage 
conditions (4.0 ± 0.5 ºC). 
 
3.3. Effects of pH on the stability and redispersibility of PZQ aqueous nanosuspensions 
The pH of the dispersion media has been classically described to display a significant effect on 
the electrical surface charge of many drugs (and polymers) of pharmaceutical interest (Arias et al. 
2008, 2009; Cózar-Bernal et al., 2010; Ruiz et al., 2004). Therefore, it was relevant to analyse how 
the colloidal stability of the anthelmintic drug depended on [H
+
]. 
Fig. 5a exemplifies the type of time evolution registered for the F (%) of the PZQ 
nanosuspensions at three pH values (sedimentation versus time curves). Generally speaking, V0 was 
very low and progressively increased with time, so that ≈ 60 h were needed to get a constant low Vs. 
It can be additionally identified in the figure a slight trend towards lower sedimentation values as 
the pH was increased. Again and as previously postulated in Section 3.2., the hydrophobic character 
of the PZQ particles (see Section 3.1.) could be behind the small differences found in the 
sedimentation profiles. 
These results were verified by the relative absorbance versus time curves (Fig. 5b): the slight 
trend for lower sedimentation values as the pH increases (plotted in Fig. 5a) was confirmed, 
possibly a consequence of the lower weight of these lightly less voluminous flocculi. 
These results could be qualitatively explained in the context of the DLVO classical theory of the 
stability of hydrophobic colloids (Hunter, 2001). As can be observed in Fig. 6, PZQ nanoparticles 
showed a well-defined isoelectric point (pHiep or pH of zero ζ) in the vicinity of pH 3.7. As pH 
became more acidic, the decrease in |ζ| values could come from neutralization of the negative 
regions at the drug surface by adsorption of increasing quantities of H
+
 ions (Arias et al. 2008, 
Cózar-Bernal et al., 2010; Ruiz et al., 2004). This dependence of the surface electrical charge of the 
solid with the pH of the dispersion media may explain the stability and redispersibility of the PZQ 











may favour aggregation of voluminous flocculi, also characterized by a large weight, by van der 
Waals attraction, and these aggregates generated visible sediments in a short period of time (fast 
sedimentation). Despite the hydrophobic attraction between the solids, the average distance between 
them could be slightly large and the nanosuspensions would be easily redispersible even by mild 
shaking. Concretely, complete redispersion of the sediments was possible after ≈ 1 min of ultrasonic 
shaking at acid pHs. 
On the contrary, at higher pH values (basic pHs), electrostatic double layer repulsions between 
the drug particles should take place due to their larger electrokinetic potential (Fig. 6). The 
nanosuspension could now be considered colloidally stable, this determining lower F (%) values in 
Fig. 5a and the slightly higher A/A0 values in Fig. 5b. PZQ solids are expected to settle as individual 
particles that will pack efficiently into a compact sediment, smaller than at acid pHs (despite the 
hydrophobic character of the drug), slightly difficult to redisperse (total redispersion after ≈ 4 min 
of ultrasonic shaking). 
Finally, and similarly to what was described in Section  3.2., the original particle size was kept 
constant (≈ 600 nm) up to five months in the flocculated PZQ nanosuspensions (see Table 2), 
presumably meaning the absence of irreversible aggregation under the standard storage conditions 
(4.0 ± 0.5 ºC). 
 
4. Conclusions 
Stability (and redispersibility) of praziquantel nanosuspensions is essentially controlled by: i) the 
hydrophobic character of this anthelmintic drug; and, ii) the electrokinetics of the particles and the 
thickness of their ionic double layers. Although the former property intensely determines the 
flocculation curves, modification of pH and incorporation of electrolytes may contribute to the 
control of the stability of the colloids. The combined use of moderate or even low concentrations of 
AlCl3 and acidic pHs should allow the formulation of praziquantel aqueous nanosuspensions with 











of this BCS Class II drug in the form of a nanosuspension could be a promising method to improve 
the poor solubility limiting its in vivo bioavailability due to a low dissolution rate in gastrointestinal 
fluids following oral administration. Additional preformulation studies are needed to include 
additional excipients in a final liquid PZQ dosage form, e.g. flavouring agents for enhancing patient 
acceptance (given the disgusting taste of pure drug and electrolytes), and polymers and surfactants 
(e.g. poloxamers, polyvinyl alcohol, polyvinylpyrrolidone, or sodium lauryl sulfate, to gain the 
benefits of a steric stabilization). 
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Figure 1. Flocculation ratio (F, Vs/V0, %) (a), and (b) optical absorbance A (relative to its initial 



















Figure 2. Flocculation ratio (F, Vs/V0, %) (a), and (b) optical absorbance A (relative to its initial 



















Figure 3. Flocculation ratio (F, Vs/V0, %) (a), and (b) optical absorbance A (relative to its initial 



















Figure 4.  Zeta potential (ζ, mV) of PZQ nanoparticles as a function of the concentration of NaCl 













Figure 5. Flocculation ratio (F, Vs/V0, %) (a), and (b) optical absorbance A (relative to its initial 
value, A0), as a function of time for PZQ aqueous dispersions at pH 3 (○), 6 (□), and 9 (◊), in the 
presence of 10
-3












Figure 6. Zeta potential (ζ, mV) of PZQ nanoparticles as a function of pH in the presence of 10
-3
 












Table 1. Effects of electrolyte type and concentration on the redispersibility of PZQ aqueous 
nanosuspensions stored under standard conditions (4.0 ± 0.5 ºC): aspect on visual inspection, and 
evolution with time of the particle size. The values are the mean ± standard deviation (SD) of 
triplicate experiments. 
Electrolyte type and 
concentration 
Size (nm) 
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 













10-5 M CaCl2 
















10-5 M AlCl3 












































Table 2. Effects of pH on the redispersibility of PZQ aqueous nanosuspensions stored under standard 
conditions (4.0 ± 0.5 ºC): aspect on visual inspection, and evolution with time of the particle size. The 
values are the mean ± standard deviation (SD) of triplicate experiments.  
pH 
Size (nm) 
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 
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